Page last updated: 2024-10-27

fleroxacin and Bacterial Pneumonia

fleroxacin has been researched along with Bacterial Pneumonia in 2 studies

Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.

Research Excerpts

ExcerptRelevanceReference
" The once daily dosage of fleroxacin [400 mg once daily intravenously (i."2.68Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. ( Marklein, G, 1996)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Marklein, G1
Ragnar Norrby, S1

Trials

2 trials available for fleroxacin and Bacterial Pneumonia

ArticleYear
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
    Chemotherapy, 1996, Volume: 42 Suppl 1

    Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Double-Blind Method; Female; Fle

1996
Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:4

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia Infections; Community-Acq

1997